Flutafuranol F 18 - AstraZeneca/Navidea Biopharmaceuticals

Drug Profile

Flutafuranol F 18 - AstraZeneca/Navidea Biopharmaceuticals

Alternative Names: [18F]-AZD4694; [18F]-NAV4694; AZD-4694; NAV-4694

Latest Information Update: 03 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AstraZeneca
  • Class Benzofurans; Fluorinated hydrocarbons; Imaging agents; Radioisotopes; Radiopharmaceutical diagnostics; Radiopharmaceuticals; Small molecules
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Alzheimer's disease

Highest Development Phases

  • Phase III Alzheimer's disease

Most Recent Events

  • 27 Oct 2017 Navidea Biopharmaceuticals signs a non-binding letter of intent to sublicense development and commercial rights of flutafuranol F 18 to Cerveau Technologies in Australia, Canada, China and Singapore
  • 08 Aug 2016 Navidea Biopharmaceuticals enters a term sheet agreement for sub-licensing Flutafuranol F 18 to Cerveau Technologies
  • 12 Feb 2016 Phase-III development is ongoing in USA (NCT01886820)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top